Skip to main content
SpringerLink
Log in

Symposium Drugs Effecting Cholesterol Disposition

  • Conference paper
Verhandlungen der Deutschen Gesellschaft für innere Medizin

Part of the book series: Verhandlungen der Deutschen Gesellschaft für innere Medizin ((VDGINNERE,volume 89))

  • 24 Accesses

Zusammenfassung

Levels of plasma lipoproteins are regulated by the balance between their production and clearance. Although great attention has been paid to mechanisms for clearance of lipoproteins from plasma, work on factors regulating the production of lipoproteins has been limited. In recents Years, however, our laboratory has become interested in the role of lipoprotein production in the regulation of their levels. This work has been concerned with two major moieties of the plasma lipoproteins, namely, triglycerides and apolipoprotein B (apo B). Triglycerides (TG) are the major lipid constituent of very low density lipoproteins (VLDL), and apo B is the major apoprotein of both VLDL and low density lipoproteins (LDL). Our findings suggest that overproduction of these constituents is an important factor in the development of hyperlipoproteinemia. Of particular interest, we have found that overproduction of lipoproteins occurs in many different forms of hyperlipidemia, and it may be an underlying defect in these several types. The following discussion will consider the spectrum of disorders associated with overproduction of lipoproteins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Goldstein JL, Hazzard WR, Schrott HG et al. (1973) J Clin Invest 52: 1533

    Article  PubMed  CAS  Google Scholar 

  2. Goldstein JL, Hazzard WR, Schrott HG et al. (1973) J Clin Invest 52: 1544

    Article  PubMed  CAS  Google Scholar 

  3. Chait A, Albers JJ, Brunzell JD (1980) Eur J Clin Invest 10: 17

    PubMed  CAS  Google Scholar 

  4. Janus ED, Nicoll AM, Turner PR et al. (1980) Eur J Clin Invest 10: 161

    Article  PubMed  CAS  Google Scholar 

  5. Kissebah AH, Alfarsi S, Adams PW (1981) Metabolism 30: 856

    Article  PubMed  CAS  Google Scholar 

  6. Vega GL, Illingworth DR, Grundy SM et al. (1983) Metabolism 32: 118

    Article  PubMed  CAS  Google Scholar 

  7. Beil U, Grundy SM, Crouse JR et al. (1982) Arteriosclerosis 2: 44

    Article  PubMed  CAS  Google Scholar 

  8. Dunn FL, Bilheimer DW, Raskin P, Grundy SM (1983) Clin Res 31: 385A

    Google Scholar 

  9. Havel RJ (1982) Med Clin North Am 66: 441

    PubMed  CAS  Google Scholar 

  10. Goldstein JL, Brown MS (1982) Med Clin North Am 66:335

    PubMed  CAS  Google Scholar 

  11. Brunzell JD, Schrott HG, Motulsky AG et al. (1976) Metabolism 25: 313

    Article  PubMed  CAS  Google Scholar 

  12. Kesaniemi YA, Grundy SM (1983) Arteriosclerosis 3: 40

    Article  PubMed  CAS  Google Scholar 

  13. Kesaniemi YA, Grundy SM (1983) Arteriosclerosis 3: 170

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Thorp JM, Warning WS (1962) Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 194: 948

    Article  PubMed  CAS  Google Scholar 

  2. Stamler J (1975) The coronary drug project. JAMA 231: 360

    Article  Google Scholar 

  3. Committee of Principal Investigators (1978). A cooperative trial in the prevention of ischaemic heart disease using clofibrate. Br Heart J 40: 1069

    Article  Google Scholar 

  4. Report of the Committee of Principal Investigators (1980) WHO cooperative trial in primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 2: 379

    Google Scholar 

  5. Rössner S, Oxö L (1981) Fenofibrate therapy of hyperlipoproteinemia a dose-response study and a comparison with clofibrate. Atherosclerosis 38: 273–282

    Article  PubMed  Google Scholar 

  6. Kannel WB, Castelli WP, Gordon T, McNamara PM (1961) Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann Intern Med 55: 33

    PubMed  CAS  Google Scholar 

  7. sCheng CY, Feldman EB (1971) Clofibrate, inhibitor of intestinal cholesterogenesis. Biochem Pharmacol 20: 3509

    Article  PubMed  CAS  Google Scholar 

  8. sAdams LL, Webb WW, Fallon HJ (1971) Inhibition of hepatic triglyceride formation by clofibrate. J Clin Invest 50: 2339

    Article  PubMed  CAS  Google Scholar 

  9. Duncan CH, Best MM (1964) Inhibition of hepatic secretion of triglycerides by chlorophenoxyisobutyrate (CPIB). Circulation 30: 111

    Google Scholar 

  10. Rifkind BM (1966) Effect of CPIB ester on plasma free fatty acid levels in man. Metabolism 15: 673

    Article  PubMed  CAS  Google Scholar 

  11. Grundy SM, Ahrens EH Jr, Salen G (1972) Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res 13: 531

    PubMed  CAS  Google Scholar 

  12. White LW (1971) Regulation of hepatic cholesterol biosynthesis by clofibrate administration. J Pharmacol Exp Ther 178: 361

    PubMed  CAS  Google Scholar 

  13. Kather H, Simon-Crisan G, Simon B (1976) Inhibition of human fat cell adenylate cyclase by clofibrate. Horm Metab Res 8:146

    Article  Google Scholar 

  14. Greten H, Laible V, Zipperle G, Augustin J (1977) Comparison of assay methods for selective measurement of plasma lipases — the effect of clofibrate on hepatic and lipoprotein lipase in normals and patients with hypertriglyceridemia. Atherosclerosis 26: 563–572

    Article  PubMed  CAS  Google Scholar 

  15. Klose G, Behrendt J, Vollmar J, Greten H (1980) Effect of bezafibrate on the activity of lipoprotein lipase and hepatic triglyceride hydrolase in healthy volunteers. In: Greten H, Lang PD, Schettler G (eds) Lipoproteins and coronary heart disease. G. Witzstrock, Baden-Baden, pp 179–184

    Google Scholar 

References

  1. Tedeschi RE, Martz BL, Taylor HA, Cerimele BJ (1982) Safety and effectiveness of probucol as a cholesterol lowering agent. Artery 10: 22–34

    PubMed  CAS  Google Scholar 

  2. Miettinen TA, Huttunen JK, Kuusi T, Kumlin T, Mattila S, Naukkarinen V, Strandberg T (1982) Clinical experience with probucol with special emphasis on mode of action and long-term treatment. Artery 10: 35–43

    PubMed  CAS  Google Scholar 

  3. Baker SG, Joffe BI, Mendelsohn D, Seftel HC (1982) Treatment of homozygous familial hypercholesterolemia with probucol. S Afr Med J 62: 7–11

    PubMed  CAS  Google Scholar 

  4. Miettinen TA, Huttunen JK, Ehnholm C, Kumlin T, Mattila S, Naukkarinen V (1980) Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-II. Atherosclerosis 36: 249–259

    Article  PubMed  CAS  Google Scholar 

  5. Mellies MJ, Gartside PS, Glatfelter L, Vink P, Guy G, Schonfeld G, Glueck CJ (1980) Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A 1 and A 2 in adults with primary familial hypercholesterolemia. Metabolism 29: 956–964

    Article  PubMed  CAS  Google Scholar 

  6. DeLorier J, Du-Breuil-Quidoz S, Lussier-Cacan S, Huang Y-S, Davignon J (1977) Diet and probucol in lowering cholesterol concentrations. Arch Intern Med 137: 1429–1434

    Article  Google Scholar 

  7. Miettinen TA (1972) Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesterolemia. Atherosclerosis 15: 163–176

    Article  PubMed  CAS  Google Scholar 

  8. Jirsa M, Marecek Z, Kerdac V, Kucerova L (1982) Effect of probucol on bile composition in man. Artery 10: 44–47

    PubMed  CAS  Google Scholar 

  9. Nestel PJ, Billington T (1981) Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis 38: 203–209

    Article  PubMed  CAS  Google Scholar 

  10. Kesäniemi YA, Grundy SM (1982) Low density lipoprotein (LDL) levels can be lowered by two mechanisms: increasing removal and decreasing production. 6th International Symposium on Atherosclerosis. Berlin (Abstract 2)

    Google Scholar 

  11. Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, Kagan A, Zukel WJ (1977) HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 55: 767–772

    PubMed  CAS  Google Scholar 

  12. Miettinen TA, Huttunen JK, Strandberg T, Naukkarinen V, Mattila S, Kumlin T (1981) Lowered HDL cholesterol and incidence of ischaemic heart disease. Lancet 2: 478

    Article  PubMed  CAS  Google Scholar 

  13. Sedaghat A, Samuel P, Crouse JR, Ahrens EH Jr (1975) Effects of neomycin on absorption, synthesis and/or flux of cholesterol in man. J Clin Invest 55: 12–21

    Article  PubMed  CAS  Google Scholar 

  14. Miettinen TA (1979) Effects of neomycin alone and in combination with cholestyramine on serum cholesterol and fecal steroids in hypercholesterolemic subjects. J Clin Invest 64: 1485–1493

    Article  PubMed  CAS  Google Scholar 

  15. Thompson GR, Barrowman J, Gutierrez L, Dowling RH (1971) Action of neomycin on the intraluminal phase of lipid absorption. J Clin Invest 50: 319–323

    Article  PubMed  CAS  Google Scholar 

  16. Miettinen TA (1975) Mechanism of action of nonabsorbable lipid-lowering drugs. Proc 6th Int Congr Pharmacol Drug Ther 4: 149–158

    Google Scholar 

  17. Miettinen TA (1982) Effects of neomycin alone and in combination with cholestyramine on serum methyl sterols and conversion of acetate and mevalonate to cholesterol. Scand J Clin Lab Invest 42: 189–196

    Article  PubMed  CAS  Google Scholar 

  18. Samuel P, Holtzman CM, Meilman E, Perl W (1968) Effect of neomycin on exchangeable pools of cholesterol in the steady state. J Clin Invest 47: 1806–1818

    Article  PubMed  CAS  Google Scholar 

  19. Vuoristo M (1979) Cholesterol metabolism in adult coeliac disease. Thesis, University of Helsinki, Finland

    Google Scholar 

  20. Vuoristo M, Miettinen TA (1982) Cholesterol absorption, elimination and synthesis in coeliac disease. Eur J Clin Invest 12: 285–291

    Article  PubMed  CAS  Google Scholar 

References

  • Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan M, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsten K, Liesch J, Springer J (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77: 3957–3961

    Article  PubMed  CAS  Google Scholar 

  • Betteridge DJ, Krone W, Reckless JPD, Galton DJ (1978) Compactin inhibits cholesterol synthesis in lymphocytes and intestinal mucosa from patients with familial hypercholesterolemia. Lancet 2: 1342–1343

    Article  PubMed  CAS  Google Scholar 

  • Brown MS, Faust JR, Goldstein JL (1978) Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253: 1121–1128

    PubMed  CAS  Google Scholar 

  • Brown MS, Goldstein JL (1980) Multivalent feedback regulation of HMG CoA reductase; a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21: 505–517

    PubMed  CAS  Google Scholar 

  • Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH (1976) Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc [Perkin] 1: 1165–1170

    Article  Google Scholar 

  • DePierre JW, Ernster L (1977) Enzyme topology of intracellular membranes. Annu Rev Biochem 46: 201–262

    Article  PubMed  CAS  Google Scholar 

  • Endo A (1979) Monakolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiotics 32: 852–854

    Article  CAS  Google Scholar 

  • Endo A, Kuroda M, Tsujita Y (1976) ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot (Tokyo) 29: 1346–1348

    Article  CAS  Google Scholar 

  • Goldstein JL, Brown MS (1975) Familial hypercholesterolemia: a genetic regulatory defect in cholesterol metabolism. Am J Med 58: 147–150

    Article  PubMed  CAS  Google Scholar 

  • Goldstein JL, Brown MS (1977) The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 46: 897–930

    Article  PubMed  CAS  Google Scholar 

  • Goldstein JL, Brown MS (1979) The LDL receptor locus and the genetics of familial hypercholesterolemia. Annu Rev Genet 13: 259–289

    Article  PubMed  CAS  Google Scholar 

  • Kesäniemi YA, Witztum JL, Steinbrecher UP (1983) Receptor-mediated catabolism of low density lipoprotein in man — quantitation using glucosylated low density lipoprotein. J Clin Invest (in press)

    Google Scholar 

  • Kovanen PT, Bilheimer DW, Goldstein JL, Jaramillo JJ, Brown MS (1981) Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA 78: 1194– 1198

    Article  PubMed  CAS  Google Scholar 

  • Kuroda M, Tsujita Y, Tanzawa K, Endo K (1979) Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Lipids 14: 585–589

    Article  PubMed  CAS  Google Scholar 

  • Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, Watanabe A, Koizumi J, Takeda R (1981) Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med 305: 478–482

    Article  PubMed  CAS  Google Scholar 

  • Mabuchi H, Sakai T, Sakai Y, Yoshimura A, Watanabe A, Wakasugi T, Koizumi J, Takeda R (1983) Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N Engl J Med 308: 609–613

    Article  PubMed  CAS  Google Scholar 

  • Rodwell VW, Nordstrom JL, Mitschelen JJ (1976) Regulation of HMG CoA reductase. Adv Lipid Res 14: 1–74

    PubMed  CAS  Google Scholar 

  • Shepherd J, Bicker S, Lorimer AR, Packard CJ (1979) Receptormediated low density lipoprotein catabolism in man. J Lipid Res 20: 999–1006

    PubMed  CAS  Google Scholar 

  • Steinbrecher UP, Witztum JL, Kesäniemi YA, Elam RE (1983) Comparison of glucosylated LDL with methylated or cyclohexanedione-treated LDL in the measurement of receptor-mediated LDL catabolism. J Clin Invest (in press)

    Google Scholar 

  • Tobert JA, Bell GD, Birtwell J, James I, Kukovetz WR, Pryor JS, Buntinx A, Holmes IB, Chao Y-S, Bolognese JA (1982) Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydro-xy-3-methylglutaryl-coenzyme A reductase in healthy volunteers. J Clin Invest 69: 913–919

    Article  PubMed  CAS  Google Scholar 

  • Tsujita Y, Kuroda M, Tanzawa K, Kitano N, Endo A (1979) Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis 32: 307–313

    Article  PubMed  CAS  Google Scholar 

  • Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D (1982) Nonenzymatic glucosylation of low density lipoprotein alters its biologic activity. Diabetes 31: 283–291

    Article  PubMed  CAS  Google Scholar 

  • Yamamoto A, Sudo H, Endo A (1980) Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 35: 259–266

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Admirand WH, Small DM (1968) The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest 47: 1043–1052

    Article  PubMed  CAS  Google Scholar 

  2. Ahlberg J et al. (1979) Prevalence of gallbladder disease in hyperlipoproteinemia. Dig Dis Sci 24: 459–464

    Article  PubMed  CAS  Google Scholar 

  3. Ahlberg J (1979) Biliary lipid metabolism in hyperlipoproteinaemia and gallstone disease. Acta Chir Scand [Suppl] 492: 1–32

    CAS  Google Scholar 

  4. Ahlberg J et al. (1980) Biliary lipid composition in normo- and hyperlipoproteinemia. Gastroenterology 79: 90–94

    PubMed  CAS  Google Scholar 

  5. Andersen E et al. (1980) On the metabolism of cholesterol and bile acids in normo- and hyperlipidaemic subjects. Acta Med Scand [Suppl 643]

    Google Scholar 

  6. Anderson E, Hellstroem K (1979) The effect of cholesterol feeding on bile acid kinetics and biliary lipids in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 20: 1020–1027

    Google Scholar 

  7. Angelin B et al. (1979) Biliary lipid composition during treatment with different hypolipidaemic drugs. Eur J Clin Invest 9: 185–190

    Article  PubMed  CAS  Google Scholar 

  8. Angelin B et al. (1981) Clofibrate treatment and bile cholesterol saturation: short-term and long-term effects and influence of combination with chenodeoxycholic acid. Eur J Clin Invest 11: 185–189

    Article  PubMed  CAS  Google Scholar 

  9. Bateson MC et al. (1978) Reversal of clofibrate-induced cholesterol oversaturation of bile with chenodeoxycholic acid. Br Med J 1: 1171–1173

    Article  PubMed  CAS  Google Scholar 

  10. Begemann F et al. (1978) The influence of beta-sitosterol on biliary cholesterol saturation and bile acid kinetics in man. Scand J Gastroenterol 13: 57–63

    Article  PubMed  CAS  Google Scholar 

  11. Bennion LJ et al. (1980) Oral contraceptives raise the cholesterol saturation of bile by increasing biliary cholesterol secretion. Metabolism 29: 18–22

    Article  PubMed  CAS  Google Scholar 

  12. Bennion LJ, Grundy SM (1975) Effects of obesity and caloric intake on biliary lipid metabolism in man. J Clin Invest 55: 996– 1011

    Article  Google Scholar 

  13. Bennion LJ, Grundy SM (1978) Risk factors for the development of cholelithiasis in man. N Engl J Med 299: 1161–1167, 1221–1227

    Article  PubMed  CAS  Google Scholar 

  14. Bennion LJ et al. (1980) Oral contraceptives raise the cholesterol saturation of bile by increasing biliary cholesterol secretion. Metabolism 29: 18–22

    Article  PubMed  CAS  Google Scholar 

  15. Boston Collaborative Drug Surveillance Program (1973) Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet 1: 1399–1404

    Google Scholar 

  16. Boston Collaborative Drug Surveillance Program (1974) Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 290: 15–19

    Google Scholar 

  17. Cooper J et al. (1975) Clofibrate and gallstones. Lancet 1: 1083

    Article  PubMed  CAS  Google Scholar 

  18. Coronary Drug Project Research Group (1977) Gallbladder disease as a side effect of drugs influencing lipid metabolism. N Engl J Med 296: 1185–1190

    Google Scholar 

  19. Einarsson K et al. (1975) Gallbladder disease in hyperlipoproteinaemia. Lancet 1: 484–487

    Article  PubMed  CAS  Google Scholar 

  20. Friedmann GD et al. (1966) The epidemology of gallbladder disease: observations in the Framingham study. J Chronic Dis 19: 273–292

    Article  Google Scholar 

  21. Greten H et al. (1979) Lipoproteine und Herzinfarkt. Neue Aspekte in Diagnostik und Therapie von Hyperlipidaemien. Witzstrock, Baden Baden Köln New York

    Google Scholar 

  22. Grundy SM (1975) Effects of polyunsaturated fats on lipid metabolism in patients with hypertriglyceridemia. J Clin Invest 55: 269–282

    Article  PubMed  CAS  Google Scholar 

  23. Grundy SM et al. (1972) Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res 13: 531–551

    PubMed  CAS  Google Scholar 

  24. Grundy SM, Mok HYI (1976) Effects of low dose phytosterols on cholesterol adsorption in man. In: Greten H (ed) Lipoprotein metabolism. Springer, Berlin Heidelberg New York, pp 112–118

    Chapter  Google Scholar 

  25. Grundy SM, Mok HYI (1979) Effect of diets and drugs on biliary cholesterol secretion in man. In: Fischer MM, Goresky CA, Shaffer EA, Strasberg SM (eds) Gall stones. Plenum Publ. Corp., New York, pp 283–298

    Google Scholar 

  26. Grundy SM et al. (1981) Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 22: 24–36

    PubMed  CAS  Google Scholar 

  27. Hellstroem K, Einarsson K (1977) Bile acid metabolism in hyperlipoproteinaemia. Clin Gastroenterol 6: 103–128

    CAS  Google Scholar 

  28. Hill GL et al. (1975) Gallstones after ileostomy and ileal resection. Gut 16: 932–936

    Article  PubMed  CAS  Google Scholar 

  29. Lageder H (1980) Vergleichende Doppelblinduntersuchung von Bezafibrat und Clofibrat bei Patienten mit primärer Hyperlipoproteinämie. Wien Klin Wochenschr 92: 95–101

    PubMed  CAS  Google Scholar 

  30. Mentzer SH (1926) A clinical and pathological study of cholecystitis and cholelithiasis. Surg Gynecol Obstet 42: 782–793

    Google Scholar 

  31. Micheli H et al. (1979) Treatment of hyperlipoproteinemia type IIa with a new phenoxy-isobutiric acid derivate, procetofene. Int J Clin Pharmacol 17: 503–506

    CAS  Google Scholar 

  32. Miettinen TA (1978) Effects of neomycin alone and in combination with cholestyramine on serum cholesterol and fecal steroids in hypercholesterolemic subjects. J Clin Invest 64: 1485–1493

    Article  Google Scholar 

  33. Mordasini R (1978) Therapie der Hyperlipoproteinaemien — wann? wie? Schweiz Med Wochenschr 108:113–119

    PubMed  CAS  Google Scholar 

  34. Morganroth J et al. (1975) The biochemical, clinical and genetic features of type III hyperlipoproteinemia. Ann Intern Med 82: 158–162

    PubMed  CAS  Google Scholar 

  35. Nilson S (1966) Gallbladder disease and sex hormons. A statistical study. Acta Chir Scand 132: 275–279

    Google Scholar 

  36. Olsson AG, Lang PD (1978) Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 31: 421–428

    Article  PubMed  CAS  Google Scholar 

  37. Pertsemlidis D et al. (1974) Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology 66: 565–573

    PubMed  CAS  Google Scholar 

  38. Roessner S, Oroe L (1978) Effects on serum lipoproteins of procetofene in hyperlipoproteinemia: dose-response studies and comparison with clofibrate. In: Carlson LA et al. (eds) International Conference on Atherosclerosis. Raven Press, New York, pp 135–140

    Google Scholar 

  39. Schlierf G et al. (1980) In: Kohlmeier M, Oster P, Stiehl A (eds) Biliary and plasma lipids and lipid-lowering chemotherapy — studies with clofibrate, fenofibrate and etofibrate in healthy volunteers. Atherosclerosis 36: 323–329

    Google Scholar 

  40. Schlierf G et al. (1980) Gallenlipide unter Bezafibrat. Münch Med Wochenschr 122: 165–168

    CAS  Google Scholar 

  41. Sedaghat A et al. (1975) Effects of neomycin on absorption, synthesis, and/or flux of cholesterol in man. J Clin Invest 55: 12–21

    Article  PubMed  CAS  Google Scholar 

  42. Sturdevant RAL et al. (1973) Increased prevalence of cholelithiasis in men ingesting a serum-cholesterol-lowering diet. N Engl J Med 288: 24–27

    Article  PubMed  CAS  Google Scholar 

  43. Tangedahl TN et al. (1979) Biliary lipid secretion in hypercholesterolemia. J Lipid Res 20: 125–133

    PubMed  CAS  Google Scholar 

  44. Von Bergmann K et al. (1981) Effects of lipid lowering substances on biliary lipid metabolism in hyperlipidaemic patients. In: Lipoproteins and coronary atherosclerosis. Lugano, October 1-–3. (Abstract book) p 190

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Human Nutrition, Health Science Center, Univ. of Texas, Dallas, USA

    S. M. Grundy

  2. Inst. für Humangenetik, Univ. Marburg, Deutschland

    G. Utermann

  3. Med. Kern- und Poliklinik, Univ.-Krankenhaus Eppendorf, Hamburg, Deutschland

    H. Greten & G. Klose

  4. Karolinska Inst., Konung Gustai V. Forskninginst., Stockholm, Sweden

    L. A. Carlson

  5. Second Dept. of Medicine, Univ. of Helsinki, Finland

    T. A. Miettinen

  6. Second Dept. of Medicine, Univ. of Helsinki, Finland

    Y. A. Kesäniemi

  7. Med. Univ.-Klinik, Bonn, Deutschland

    K. von Bergmann

Authors
  1. S. M. Grundy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Utermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Greten
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Klose
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. A. Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. A. Miettinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y. A. Kesäniemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. von Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kliniken der Landeshauptstadt Wiesbaden, Wiesbaden, D-6200, Deutschland

    Bernhard Schlegel

Rights and permissions

Reprints and permissions

Copyright information

© 1983 J. F. Bergmann Verlag, München

About this paper

Cite this paper

Grundy, S.M. et al. (1983). Symposium Drugs Effecting Cholesterol Disposition. In: Schlegel, B. (eds) Verhandlungen der Deutschen Gesellschaft für innere Medizin. Verhandlungen der Deutschen Gesellschaft für innere Medizin, vol 89. J.F. Bergmann-Verlag. https://doi.org/10.1007/978-3-642-85456-9_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85456-9_28

  • Publisher Name: J.F. Bergmann-Verlag

  • Print ISBN: 978-3-8070-0335-1

  • Online ISBN: 978-3-642-85456-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation